Meronem (Meropenem)

Meropenem works by binding to penicillin‑binding proteins (PBPs) located on the bacterial cell wall. This inhibits the final transpeptidation step of peptidoglycan synthesis, weakening the cell wall and causing osmotic lysis of the bacterium. Its structure also resists most β‑lactamases, allowing activity against many resistant strains.

The dosage of Meronem is individualized by the prescribing clinician based on the type and severity of infection, the patient’s renal function, age and weight. Dosing regimens are typically expressed in milligrams per kilogram administered intravenously every 8 hours, but exact amounts must be determined by a qualified healthcare professional.

Meronem is classified as Pregnancy Category B, indicating that animal studies have not shown a risk to the fetus and there are no adequate human studies. It should be used during pregnancy only if clearly needed. Limited data are available for breastfeeding; the drug is excreted in milk, so a risk‑benefit assessment should be performed by the prescriber.

To request Meronem, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing a quotation, confirming availability, shipping conditions and any necessary import documentation.

Meronem (meropenem) shares the carbapenem class with agents such as imipenem‑cilastatin and ertapenem. Compared with imipenem, meropenem has a broader spectrum against Pseudomonas aeruginosa and is less likely to cause seizures. Unlike ertapenem, meropenem is administered three times daily and provides coverage for Acinetobacter species, making it suitable for more severe, multi‑drug‑resistant infections.

Meronem powder for injection must be stored refrigerated at 2 °C to 8 °C. The vials should be kept in their original packaging, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and stored according to the same temperature requirements.

Meronem is supplied as a sterile powder that is reconstituted with a compatible diluent to form an injectable solution. The solution is administered intravenously, usually over 15–30 minutes, through a peripheral or central line. Administration rate and infusion volume are determined by the prescriber and may be adjusted for renal function or specific clinical situations.

The most serious adverse reactions to Meronem include seizures, especially in patients with renal impairment or pre‑existing central nervous system disorders, and severe hypersensitivity reactions such as anaphylaxis. Additionally, Clostridioides difficile‑associated colitis can occur and may be life‑threatening. Prompt recognition and medical intervention are essential if any of these events arise.

Meronem should be avoided in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving concomitant valproic acid, as the drug may lower seizure threshold or reduce valproic acid levels. In such cases, alternative therapy should be considered.